

Date: 6<sup>th</sup> June, 2026

To,  
The Manager,  
Department of Corporate Services,  
BSE Limited  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001  
Scrip Code: 533573

To,  
The Manager,  
Listing Department,  
National Stock Exchange of India Ltd.  
'Exchange Plaza', Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
NSE Symbol: APL LTD

Dear Sir/Madam,

**Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that Alembic Pharmaceuticals Limited (the “Company”) has executed a Shareholders’ Agreement to invest in a newly incorporated Canadian Corporation.

The Company will hold a 45% equity stake, in the Canadian Corporation pursuant to the Shareholders’ Agreement.

The details as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30<sup>th</sup> January 2026 is attached herewith as “Annexure-A”.

This is for your information and record

Yours faithfully,

**For Alembic Pharmaceuticals Limited**

**Manisha Saraf**  
**Company Secretary**

**ALEMBIC PHARMACEUTICALS LIMITED**

REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. • TEL: (0265) 2280550, 2280880 • FAX: (0265) 2281229  
Website : [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com) • E-mail : [alembic@alembic.co.in](mailto:alembic@alembic.co.in) • CIN : L24230GJ2010PLC061123

**Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) read with Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30<sup>th</sup> January 2026:**

<b>Sr. No.</b>	<b>Particulars</b>	<b>Details</b>
1.	Name(s) of parties with whom the agreement is entered;	Alembic Pharmaceuticals Limited (the “Company”) has executed a Shareholders’ Agreement along with Difgen Holdings LLC (“Difgen”) and Mr. Sukhad Juneja (collectively be called as “parties”) for investing in shares of 17989377 Canada Inc. (the “Canadian Corporation”).
2.	Purpose of entering into the agreement;	Investment in Canadian Corporation to establish a platform for development, commercialization, distribution and marketing of pharmaceutical products focused on the Canadian market.
3.	Shareholding, if any, in the entity with whom the agreement is executed;	The shareholding of the Corporation held by each Party shall be as under: a) Alembic Pharmaceuticals Limited (45%); b) Difgen Holdings LLC (45%); and (c) Others: 10%
4.	Significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.;	The board of directors of the Canadian Corporation comprises nominee directors of the shareholders along with an independent director. The agreement also provides for customary shareholder rights including participation in key decision matters.
5.	Whether, the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship;	The parties to the Joint Venture are not related to promoter / promoter group / group company in any manner.
6.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”;	The investment in the share capital of the Canadian Corporation does not fall within the purview of Related Party Transaction for the Company.

**ALEMBIC PHARMACEUTICALS LIMITED**

		Post investment by the Company, the Canadian Corporation will become an Associate of the Company.
7.	In case of issuance of shares to the parties, details of issue price, class of shares issued;	Not Applicable
8.	Any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc.;	There is no potential conflict of interest arising out of this agreement.
9.	in case of termination or amendment of agreement, listed entity shall disclose additional details to the stock exchange(s): a) name of parties to the agreement; b) nature of the agreement; c) date of execution of the agreement; d) details of amendment and impact thereof or reasons of termination and impact thereof.	Not Applicable

## **ALEMBIC PHARMACEUTICALS LIMITED**